|
|
||||||||
1 Activity during EGF-Induced Proliferation of Corneal Epithelial Cells: Effect of Phosphoinositide-3 Kinase
From the Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta.
| Abstract |
|---|
|
|
|---|
1 (PLC
1) and phosphoinositide-3 kinase
(PI3K) activities in confluent rabbit corneal epithelial cells (RCECs).
The purpose of this study was to investigate whether PLC
1 activity
is upregulated during EGF-induced proliferation of RCECs and to
determine whether there is any cross-talk between PLC
1 and PI3K in
these cells.
METHODS. Simian virus (SV)-40immortalized RCECs were cultured in the presence
and absence of EGF and other agents. At prescribed time intervals, the
cultures were terminated and the cells counted. PLC
1 activity in
intact cells was assessed by measuring the production of
[3H]IP3 in
[3H]myoinositol-labeled cells. The in vitro enzyme
activity was assayed using immunoprecipitated PLC
1 and
[3H]PI(4,5)P2 as substrate.
[3H]IP3, the product of PLC
1, was analyzed
by anion-exchange chromatography. The changes in protein content and
level of phosphorylation of PLC
1 were determined by Western
immunoblot analysis, with the appropriate antibodies.
RESULTS. Addition of EGF (50 ng/ml) caused a time-dependent increase in
proliferation of RCECs. The effect of EGF peaked at approximately 36
hours. Under the same experimental conditions, EGF stimulated PLC
1
activity with a time course similar to that of cell proliferation. Data
from Western immunoblot analysis revealed that the EGF-stimulated
PLC
1 activity was due to increased synthesis of the enzyme.
Furthermore, during cell proliferation, tyrosine phosphorylation of
PLC
1 increased in a time-dependent manner that corresponded closely
with the expression of PLC
1. EGF exerted its effects both on cell
proliferation and PLC
1 activation in a dose-dependent manner.
Treatment of the cells with U-73122, a PLC inhibitor, or
myr-GLYRKAMRLRY, a myristoylated PLC
1 inhibitor peptide, caused
attenuation of both the EGF-stimulated cell proliferation and PLC
1
activity. Treatment of the cells with the PI3K inhibitors, wortmannin
or LY294002, caused inhibition of both EGF-stimulated cell
proliferation and PLC
1 activation. Addition of
PI(3,4,5)P3 to the in vitro PLC
1 assay mixture
stimulated the enzyme activity in a dose-dependent manner.
CONCLUSIONS. The data suggest a positive correlation between EGF-stimulated PLC
1
activation and cell proliferation in RCECs. The EGF-stimulated PLC
1
activity was mirrored by increased synthesis and tyrosine
phosphorylation of the enzyme. The data also show that PLC
1
activation and cell proliferation were inhibited by PI3K inhibitors,
suggesting a role for PI3K in EGF-stimulated proliferation of corneal
epithelial cells.
| Introduction |
|---|
|
|
|---|
, and PLC
.2
PLCß subtypes are regulated
by heterotrimeric guanosine triphosphate (GTP)-binding proteins of the
Gq subfamily. PLC
isoforms are activated by
both receptor and nonreceptor tyrosine kinases, but the regulation of
the PLC
family of enzymes is less clear. PI3Ks phosphorylate the
hydroxyl group at the 3-position of inositol in phosphoinositides to
generate PI(3)P, PI(3,4)P2 and
PI(3,4,5)P3.3
4
These
phosphoinositides are not hydrolyzed by known PLCs and therefore
do not serve to generate additional intracellular second-messenger
molecules. Recently, however, isoforms of phospholipase D, which specifically hydrolyze PI(3,4)P2 and PI(3,4,5)P3 to phosphatidic acid and the corresponding inositol phosphates, have been reported.5 PI(3,4)P2 and PI(3,4,5)P3 are present only in trace amounts in normal resting cells, but their levels increase several fold in response to many types of stimuli.3 Several studies using genetics, PI3K inhibitors, and PI3K overexpression have implicated the PI3Ks in the regulation of cell growth and differentiation, cell survival, cytoskeletal reorganization, and membrane trafficking. PI3Ks have been classified into three types on the basis of their primary structure, regulation and in vitro substrate specificity.4 Type I PI3Ks are heterodimers consisting of p85 regulatory and p110 catalytic subunits. They can phosphorylate PI, PI(4)P, and PI(4,5)P2, and are activated by receptor and nonreceptor tyrosine kinases and G-proteinlinked receptors. Type II PI3Ks have substrate specificity restricted to PI and PI(4)P, and their mode of activation remains obscure. Type III PI3Ks are homologues of Saccharomyces cerevisiae Vps34p, which phosphorylates PI exclusively and is activated by a serine/threonine (Ser/Thr) kinase.
It is known that interaction of epidermal growth factor (EGF) with its
receptor is followed by receptor dimerization and phosphorylation of
its tyrosine residues, which provides docking sites for several
SH2-containing proteins, including PLC
1 and
PI3K.2
6
The recruitment of PLC
1 and PI3K to EGF
receptors results in their tyrosine phosphorylation and activation.
Regeneration of corneal epithelium after in vivo injury begins with the
migration of epithelial cells to the wounded area. This is followed by
mitosis and cell proliferation to repair the defect. We and others have
shown that topical application of EGF to the injured cornea stimulates
cell proliferation and enhances wound repair.7
8
The same
outcome results from the addition of EGF to corneal epithelial cells in
culture.9
10
The exact biochemical events leading from EGF-receptor interaction and
culminating in enhanced cell proliferation are not well understood.
Previously, we reported that addition of EGF to quiescent corneal
epithelial cells causes activation of PLC
1 and
PI3K.11
12
Recently, we showed that activation of PI3K by
EGF, both in vivo and in vitro, correlates positively with cell
proliferation and wound repair in rabbit corneal
epithelium.8
10
The objective of the present study was to
investigate whether there is any correlation between PLC
1 activation
and corneal epithelial cell proliferation induced by EGF. In addition,
we examined the effects of PI3K on PLC
1 activation in the
EGF-treated epithelial cells. For this work, we used simian virus
(SV)-40immortalized rabbit corneal epithelial cells (RCECs), which
are capable of growing for many passages without any alteration in
their morphology or biochemical characteristics.13
14
| Materials and Methods |
|---|
|
|
|---|
1 and -ß1 polyclonal antibodies from Santa
Cruz Biotechnology (Santa Cruz, CA); PI(4,5)P2,
PI(3)P, PI(3,4)P2, and
PI(3,4,5)P3 from Biomol (Plymouth Meeting, PA);
phosphatidylserine (PS) and phosphatidylethanolamine (PE) from Avanti
Polar Lipids (Birmingham, AL); and wortmannin, LY294002, U-73122, and
U-73343 from Calbiochem (La Jolla, CA).
[3H]PIP2 (specific
radioactivity 10 Ci/mmol) was purchased from DuPont NEN (Boston, MA)
and [3H]thymidine (specific radioactivity
64 Ci/mmol) from ICN Radiochemicals (Irvine, CA).
Cell Culture
The SV-40transformed RCECs were thawed and suspended in
complete medium (DMEM/F-12 containing 40 µg/ml gentamicin, 5 µg/ml
insulin, and 10% fetal bovine serum [FBS]) and cultured in a
humidified atmosphere of 95% air-5% CO2. The
cultures were maintained by changing the medium every other day until
the cells became confluent. To initiate subculture, the confluent cells
were washed with
Ca2+-Mg2+-free warm
phosphate-buffered saline (PBS) and treated with 0.1% trypsin-0.02%
EDTA for 5 minutes at 37°C. Next, complete medium was added and the
cell suspension centrifuged at 300g for 5 minutes. The
pelleted cells were resuspended in complete medium and then seeded in a
25-cm2 culture flask at a density of 2 x
104 cells/cm2. The cultures
were maintained by changing the medium on alternate days.
Cell Proliferation Assay
Cell proliferation was assessed by counting (model Z1, Coulter,
Hialeah, FL). The cells were washed with warm
Ca2+- and Mg2+-free PBS,
trypsinized, and suspended in 2 ml complete medium. A portion (100
µl) of the cell suspension was used for cell counting. Triplicate
counts were taken for each data point. The incorporation of
[3H]thymidine into DNA was measured as
described previously.10
Briefly, subconfluent (
60%)
cultures were incubated for 36 hours with different concentrations of
EGF in DMEM containing 2 µCi/ml [3H]thymidine
(specific radioactivity, 2 Ci/mmol). The culture medium was then
removed and the cells washed in 10% trichloroacetic acid (TCA). The
precipitated DNA was dissolved in 1% SDS-0.3 N NaOH and counted in a
scintillation counter.
In Vitro Assay of PLC
1 and PLCß1
Subconfluent (
60%) cultures were serum starved for 24 hours
before treatment with EGF or other agents. At appropriate times, the
cultures were terminated and the cells scraped and homogenized in 20 mM
Tris-HCl buffer (pH 7.0) containing 5 mM MgCl2, 5
mM EDTA, 1 mM EGTA, 1 mM PMSF, 2 mM
Na3VO4, 10 µg/ml
leupeptin, and 50 µg/ml aprotinin. The homogenate was centrifuged at
600g for 10 minutes, and the resultant supernatant
quantified for protein concentration by the method of Lowry et
al.15
Supernatants (cell lysates) containing equal amounts
of protein were treated with PLC
1 or PLCß1 antibody, and the
immunoprecipitated protein was used to assay PLC activity as described
previously, with minor modifications.16
Briefly, the
reaction mixture contained 20 mM Tris-HCl buffer (pH 7.0), 0.1 M NaCl,
2 mM CaCl2, 1 mM EGTA, 1 mM EDTA, 0.1% sodium
cholate, 50 µM [3H]PIP2
(30,000 disintegrations per minute [dpm]), and the immunoprecipitated
enzyme protein in a final volume of 125 µl. The substrate was
prepared by mixing chloroform solutions of
[3H]PIP2-unlabeled
PIP2, PE, and PS at a molar ratio of 1:2:2,
respectively. After evaporation of the solvent under
N2, the lipids were suspended by sonication in
sodium cholatecontaining reaction buffer. The reaction was initiated
by addition of the enzyme protein, incubated for 30 minutes at 37°C,
and terminated by addition of 0.5 ml chloroform-methanol-concentrated
HCl (50:50:1, by volume). Next, 150 µl of 1 M HCl containing 5 mM
EGTA was added and the reaction mixture thoroughly mixed and
centrifuged. An aliquot (400 µl) of the upper aqueous phase was
removed and counted in a scintillation counter. When the effects of
PI(3)P, PI(3,4)P2, and
PI(3,4,5)P3 on the activity of PLC
1 or PLCß1
were to be determined, the immunoprecipitated enzymes were treated for
15 minutes with different concentrations of these lipids before their
addition to the reaction mixture.
Western Immunoblot Analysis
The protein content and level of tyrosine phosphorylation of
PLC
1 were determined by Western immunoblot analysis, as described
previously.11
Briefly, RCECs lysates containing equal
amounts of protein from EGF-treated and untreated cells were
immunoprecipitated using anti-PLC
1 antibody. The precipitates were
boiled in Laemmlis buffer for 5 minutes, separated by 10% SDS-PAGE,
and the proteins transferred to nitrocellulose membranes. To determine
total PLC
1 content, the membranes were successively blotted with
anti-PLC
1 primary antibody and anti-rabbit horseradish peroxidase
(HRP)-conjugated goat secondary antibody. To determine the level of
PLC
1 tyrosine phosphorylation, the blots were stripped and reprobed
successively with anti-phosphotyrosine primary antibody and anti-mouse
HRP-conjugated secondary antibody. The protein bands were visualized
using the enhanced chemiluminescence (ECL) Western detection system
(Amersham Pharmacia Biotech, Parsippany, NJ).
Synthesis of Inhibitor Peptides for PLC
1
The myristoylated PLC
1 inhibitor peptide, myr-GLYRKMRLRY
(myr-PCI(Y)), and its weaker analogue, myr-GLFRKMRLRF (myr-PC I(F)),
were synthesized (Pioneer; PerSeptive Biosystems, Framingham, MA) at
0.1 mM, using the 9-fluorenylmethoxycarbonyl (Fmoc) solid phase
chemistry. The myristoyl group was added as the free acid. The myristic
acid was treated as an amino acid using an extended coupling procedure.
Peptide purity was determined by HPLC on a C-18 reversed-phase column
and the molecular weight determined by mass spectrometry.
Statistical Analysis of the Data
Each experiment consisted of incubations that, when pooled,
yielded three independent samples for each data point. All experiments
were performed at least twice, with the results expressed as mean ± SEM. Statistical analysis was performed with Students
t-test for nonpaired data. P
0.05 was
considered significant.
| Results |
|---|
|
|
|---|
1 Activity and Tyrosine Phosphorylation
during Cell Proliferation
1
activity during cell proliferation, the serum-starved RCECs were
cultured in the presence and absence of EGF, followed by cell counting
and determination of PLC
1 activity. As shown in Figure 1A
, in the absence of EGF, there was a gradual increase in cell number
that reached a plateau at 36 hours. Addition of EGF (50 ng/ml) exerted
a large, time-dependent increase in cell proliferation, compared with
the untreated cells. When analyzed for PLC
1 activity, there was a
time-dependent increase in enzyme activity in the untreated cells (Fig. 1B)
. Treatment with EGF caused a large increase in PLC
1 activity,
compared with the untreated cells.
|
|
1
synthesis in the untreated cells (Fig. 1C)
. PLC
1 protein levels were
further increased at all time points after treatment with EGF.
Reprobing the PLC
1 immunoblot with phosphotyrosine antibody showed a
time-dependent increase in tyrosine phosphorylation of PLC
1 in
EGF-treated and untreated cells (Fig. 1D)
. There appeared to be a close
correlation between PLC
1 phosphorylation and the level of PLC
1
expression. As shown in Figure 2
, EGF caused a dose-dependent increase in cell proliferation and PLC
1
activity. The effects were observed with as low as 5 ng/ml EGF and were
maximal at 50 ng/ml EGF, followed by a slight decrease.
|
1 Activity and Cell
Proliferation
1
activity and cell proliferation, RCECs were cultured in the presence
and absence of EGF and different concentrations of the PLC inhibitor
U-73122 and its inactive analogue U-73343. The cultures were terminated
and PLC
1 immunoprecipitated and assayed for enzyme activity in
vitro. U-73122 caused a dose-dependent decrease in cell number in
EGF-treated RCECs (Fig. 3A)
. Maximal inhibition of EGF-stimulated cell proliferation was observed
at 2 µM of the inhibitor. When examined for its effect on PLC
1
activity, U-73122 caused a dose-dependent decrease in PLC
1 activity
in EGF-treated and untreated cells (Fig. 3B)
. The stimulatory effect of
EGF on PLC
1 activity was maximally inhibited in the presence of 2
µM U-73122. U-73343, the inactive analogue, failed to exert any
significant inhibitory effect on cell proliferation or PLC
1
activity. U-73122 exerted no effect on EGF-induced expression or
tyrosine phosphorylation of PLC
1 in RCECs during proliferation
(Figs. 3C
3D)
.
|
1 inhibitor peptide, was used
to further confirm the involvement of PLC
1 in EGF-stimulated cell
proliferation in RCECs. The cells were cultured in the presence of
different concentrations of the peptide before counting and
determination of PLC
1 activity in vitro. myr-PCI(Y) inhibited the
EGF-induced cell proliferation in a dose-dependent manner (Fig. 4A)
. The EGF effect was reduced by approximately 40% in the presence of
10 µM myr-PCI(Y). Unlike U-73122, the peptide did not inhibit the
PLC
1 activity in the untreated cells. However, it inhibited the
EGF-induced activation of PLC
1 in a dose-dependent manner (Fig. 4B)
.
At 10 µM myr-PCI(Y), the EGF effect was inhibited by almost 50%.
myr-PCI(F), a PCI peptide analogue, was considerably less potent in
inhibiting the EGF-induced PLC
1 activation and cell proliferation.
|
1 Activity and Cell
Proliferation
1 lies downstream of PI3K in mediating the effect of EGF
on proliferation of corneal epithelial cells. Treatment with wortmannin
caused a dose-dependent decrease in EGF-stimulated proliferation of
RCECs (Fig. 5A)
. Wortmannin also inhibited the EGF-induced activation of PLC
1in a
dose-dependent manner (Fig. 5B)
. LY294002 also caused a dose-dependent
decrease in EGF-stimulated cell proliferation and PLC
1 activity in
RCECs (Fig. 6)
.
|
|
1
1 could
be a direct target of the PI3K products. PLC
1 was immunoprecipitated
from cultured RCECs and assayed for its activity in the presence and
absence of 3-phosphoinositides. As shown in Figure 7
, PI(3,4,5)P3 increased the activation of PLC
1
in a dose-dependent manner up to 100 µM, followed by a slight
tapering off. The maximal stimulation, observed at 100 µM, then
decreased at higher concentrations of
PI(3,4,5)P3. PI(3)P and
PI(3,4)P3 did not have any significant
stimulatory effect on PLC
1 activity. Similarly,
PI(3,4,5)P3 had no effect on the activity of
PLCß1 immunoprecipitated from RCECs (data not shown).
|
| Discussion |
|---|
|
|
|---|
1, possibly
because of its translocation to, and phosphorylation by, the EGF
receptor.11
The data from the present study show that serum-starved RCECs can
proliferate, albeit at a low rate, in the absence of any exogenously
added EGF (Fig. 1A)
. The observed proliferative response is most likely
due to autocrine secretion of growth-promoting substances by cells in
the culture medium. When treated with EGF, the cells exhibited a marked
time-dependent increase in cell number. An important finding of the
present study is that, under conditions when RCECs were undergoing
active proliferation, there was a concomitant increase in PLC
1
activity both in the EGF-treated and untreated cells (Fig. 1B)
. Western
blot analysis revealed that the increased PLC
1 activity was due to
increased synthesis and tyrosine phosphorylation of the enzyme (Figs. 1C 1D)
. The effect of EGF on PLC was found to be specific for the
PLC
1 isoform. Both the activity and expression of PLCß1 remained
unchanged during cell proliferation (data not shown).
These data provide evidence that PLC
1 is involved in a signaling
pathway that mediates the EGFs effect on DNA synthesis in RCECs. The
findings are in accord with previously published reports in which
microinjection of anti-PLC
1 antibody blocked serum- and
Ras-stimulated DNA synthesis.17
In other studies,
microinjection of PLC
1 SH2 domains into
Madin-Darby canine kidney (MDCK) epithelial cells or fibroblasts
blocked the platelet-derived growth factor (PDGF)induced DNA
synthesis.18
19
Additional evidence to support the suggestion that PLC
1 is involved
in corneal epithelial cell proliferation comes from the use of the PLC
inhibitor U-73122. This inhibitor has been widely used in a number of
studies examining the role of PLC in intracellular signaling
mechanisms.20
21
In the present study, by using U-73122,
we were able to significantly inhibit the EGF-stimulated PLC
1
activation, which resulted in a corresponding decrease in EGF-induced
proliferation in RCECs (Fig. 3)
. The inhibitory effect of U-73122 was
not due to the inhibition of PLC
1 synthesis or its phosphorylation.
It has been reported that PLC
1 possesses, adjacent to its
SH2 and SH3 motifs, a PLC
inhibitor (PCI) region that strongly suppresses its catalytic
activity.22
It has been suggested that stimulation of the
cells with growth factors probably dissociates the PCI region of
PLC
1 from the catalytic region, resulting in the activation of the
enzyme. Myristoylation of PCI facilitates its entry into Swiss 3T3
cells causing inhibition of cell growth and phosphoinositide
hydrolysis.23
We used myr-PCI(Y) to further examine the
involvement of PLC
1 in RCEC proliferation. When added to RCECs,
myr-PCI(Y) suppressed the EGF-induced PLC
1 activation and cell
proliferation (Fig. 4) . The inactive structural analogue myr-PCI(F) did
not show any consistent inhibitory effect on PLC
1 activity and cell
proliferation, even when used at high concentrations. Taken together,
these data provide convincing evidence that PLC
1 is upregulated
during EGF-induced proliferation of RCECs.
Activation of EGF receptor is followed by autophosphorylation of its
tyrosine residues, which serve as high-affinity binding sites for
SH2-containing proteins, including PLC
1.
Recruitment of PLC
1 to the receptor results in tyrosine
phosphorylation and stimulation of its enzyme
activity.2
24
Tyrosine phosphorylation of PLC
1 has been
reported to be critical in transducing mitogenic signals from growth
factor receptors to the interior of the cell. In particular,
substitution of Phe for Tyr783 completely blocks the activation of
PLC
1 by PDGF in NIH 3T3 cells.25
In addition to being
activated by tyrosine phosphorylation, PLC
1 has been shown to be
stimulated by lipid-derived second messengers, such as arachidonic
acid, phosphatidic acid, and
PI(3,4,5)P3.24
The activity of
PLC
1 has been reported to be greatly enhanced by
PIP3, whereas that of the ß- or
-PLC
isozymes remains unchanged.26
Furthermore, overexpression
of PI3K in COS-7 cells causes increased activation of PLC
1 that is
reduced to the normal level when the cells are treated with PI3K
inhibitors. In other studies, the SH2 and PH
domains of PLC
1 have been found to potently bind
PIP3 generated by PI3K.19
27
To investigate whether EGF-induced PLC
1 activation in RCECs is
dependent on concomitant activation of PI3K, PLC
1 activity was
assayed in cells treated with the PI3K inhibitors wortmannin and
LY294002. The results showed that both wortmannin and LY294002
dose-dependently inhibited EGF-stimulated PLC
1 activation and cell
proliferation (Figs. 5
6)
. Because the cell number remained
essentially unchanged with increasing concentrations of wortmannin or
LY294002, it was unlikely that the inhibitory effects of these
compounds on EGF-induced responses was due to increased cell death.
When wortmannin or LY294002 was added directly to the PLC
1 assay
mixture, there was no inhibition of the enzyme activity (data not
shown), which suggests that these compounds inhibit PLC
1 by
selectively blocking PI3K activity. Further evidence that PLC
1 lies
downstream of PI3K is provided by the experiments in which PLC
1 was
assayed in the presence of 3-phosphoinositides. The enzyme activity was
markedly increased by PI(3,4,5)P3 >>
PI(3,4)P2 and PI(3)P was without effect (Fig. 7)
.
Taken together, the data provide support for the hypothesis that
EGF-induced proliferation of RCECs involves both increased PLC
1
synthesis and enzyme activation by PI(3,4,5)P3, a
product of PI3K. One likely mechanism for PLC
1 activation by
PI(3,4,5)P3 may involve recruitment of the enzyme
by PI(3,4,5)P3 to the plasma membrane adjacent to
its substrate, PIP2. The
SH2, SH3, and PH domains of
PLC
1 can specifically interact with inositol phospholipids. After
PLC
1 recruitment to the plasma membrane, the enzyme could be
activated directly by PI(3,4,5)P3.
In conclusion, the current data demonstrate a close correlation between
PLC
1 activation and cell proliferation in EGF-treated and untreated
RCECs. PLC
1 activation involved both increased PLC
1 synthesis and
tyrosine phosphorylation. Furthermore, the activity of PLC
1 was
found to be modulated by PI3K, suggesting that PLC
1 lies downstream
of PI3K. However, our studies did not provide information regarding the
exact biochemical events that follow PLC
1 activation and culminate
in increased DNA synthesis during cell proliferation. One
second-messenger molecule generated by PIP2
hydrolysis is DAG, which is a natural activator of PKC. There are
several studies suggesting that PKC can increase DNA synthesis by
activating the Raf/mitogen-activated kinase kinase (MEK)/extracellular
signal-regulated (ERK) pathway.28
29
Therefore, it is
possible that the mitogen-activated protein (MAP) kinase cascade also
plays a similar key role in EGF-stimulated wound repair in corneal
epithelium.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication July 6, 2000; revised December 13, 2000 and February 8, 2001; accepted February 23, 2001.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Rashid A. Akhtar, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912-2100. raakhtar{at}mail.mcg.edu
| References |
|---|
|
|
|---|
1 in cultured rabbit corneal epithelial cells Exp Eye Res 70,261-269[Medline][Order article via Infotrieve]
, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nck for PDGF-induced DNA synthesis: evidence for Ras-independent pathways EMBO J 15,4940-4948[Medline][Order article via Infotrieve]
1 enzymatic activity in growth factor-induced mitogenesis Mol Cell Biol 18,590-597
on the catalytic activity of phospholipase C isoforms: identification of a novel phospholipase C inhibitor region J Biol Chem 267,21844-21849
in the absence of tyrosine-phosphorylation Chem Phys Lipids 98,3-11[Medline][Order article via Infotrieve]
1 phosphorylation on tyrosine residues 783 and 1254 Cell 65,435-441[Medline][Order article via Infotrieve]
by phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 273,4465-4469
by PI 3-kinase-induced PH domain-mediated membrane targeting EMBO J 17,414-422[Medline][Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Z. Wang, H. Yang, S. D. Tachado, J. E. Capo-Aponte, V. N. Bildin, H. Koziel, and P. S. Reinach Phosphatase-Mediated Crosstalk Control of ERK and p38 MAPK Signaling in Corneal Epithelial Cells Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5267 - 5275. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Zhang, Q. Wen, S. Mergler, H. Yang, Z. Wang, V. N. Bildin, and P. S. Reinach PKC Isoform-Specific Enhancement of Capacitative Calcium Entry in Human Corneal Epithelial Cells. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3989 - 4000. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Li and L. Lu Epidermal Growth Factor-induced Proliferation Requires Down-regulation of Pax6 in Corneal Epithelial Cells J. Biol. Chem., April 1, 2005; 280(13): 12988 - 12995. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Landreville, S. Coulombe, P. Carrier, M. H. Gelb, S. L. Guerin, and C. Salesse Expression of Phospholipases A2 and C in Human Corneal Epithelial Cells Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 3997 - 4003. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |